Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
PCSK9 encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. De plus, nous expédions PCSK9 Protéines (61) et PCSK9 Kits (56) et beaucoup plus de produits pour cette protéine.
Showing 10 out of 155 products:
Human Polyclonal PCSK9 Primary Antibody pour ChIP, IHC (p) - ABIN268772
Cohen, Pertsemlidis, Kotowski, Graham, Garcia, Hobbs: Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. dans Nature genetics 2005
Show all 9 references for ABIN268772
Human Polyclonal PCSK9 Primary Antibody pour WB - ABIN493159
Yue, Averna, Lin, Schonfeld: The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population. dans Human mutation 2006
Show all 4 references for ABIN493159
Human Polyclonal PCSK9 Primary Antibody pour IHC (p), WB - ABIN782954
Lambert, Ancellin, Charlton, Comas, Pilot, Keech, Patel, Sullivan, Cohn, Rye, Barter: Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. dans Clinical chemistry 2008
Show all 3 references for ABIN782954
Human Polyclonal PCSK9 Primary Antibody pour EIA, WB - ABIN453778
McNutt, Kwon, Chen, Chen, Horton, Lagace: Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. dans The Journal of biological chemistry 2009
Show all 3 references for ABIN453778
Human Polyclonal PCSK9 Primary Antibody pour IHC, ELISA - ABIN185371
Lalanne, Lambert, Amar, Chétiveaux, Zaïr, Jarnoux, Ouguerram, Friburg, Seidah, Brewer, Krempf, Costet: Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. dans Journal of lipid research 2005
Show all 2 references for ABIN185371
Human Polyclonal PCSK9 Primary Antibody pour FACS, IHC (p) - ABIN391505
Shioji, Mannami, Kokubo, Inamoto, Takagi, Goto, Nonogi, Iwai: Genetic variants in PCSK9 affect the cholesterol level in Japanese. dans Journal of human genetics 2004
Show all 2 references for ABIN391505
Human Polyclonal PCSK9 Primary Antibody pour FACS, IHC (p) - ABIN652320
Abifadel, Varret, Rabès, Allard, Ouguerram, Devillers, Cruaud, Benjannet, Wickham, Erlich, Derré, Villéger, Farnier, Beucler, Bruckert, Chambaz, Chanu, Lecerf, Luc, Moulin, Weissenbach, Prat, Krempf et al.: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. ... dans Nature genetics 2003
Show all 2 references for ABIN652320
Human Polyclonal PCSK9 Primary Antibody pour IF (p), IHC (p) - ABIN761831
Jia, Song, Yang, Ma, Li, Lu, Cao, Zhang, Zhu, Wang, Leng, Cao, Du, Xu: Effects of Tanshinone IIA on the modulation of miR‑33a and the SREBP‑2/Pcsk9 signaling pathway in hyperlipidemic rats. dans Molecular medicine reports 2016
Human Polyclonal PCSK9 Primary Antibody pour EIA, WB - ABIN569616
Kwon, Lagace, McNutt, Horton, Deisenhofer: Molecular basis for LDL receptor recognition by PCSK9. dans Proceedings of the National Academy of Sciences of the United States of America 2008
PCSK9 levels are linearly associated with the fraction and amount of necrotic core tissue in coronary atherosclerosis, independently of serum LDL cholesterol levels and statin use
Both PCSK9 levels and CETP (Montrer CETP Anticorps) activity were higher in patients with an increasing number of metabolic syndrome components
Circulating PCSK9 levels were correlated with an atherogenic lipid profile and with insulin (Montrer INS Anticorps) resistance parameters; The rs11591147 genetic variant of PCSK9 resulted in lower levels of circulating PCSK9 and LDL cholesterol
PCSK9 increases hepatic lipid and lipoprotein production via apoE (Montrer APOE Anticorps)- and LDLR (Montrer LDLR Anticorps)-dependent mechanisms
Possible inter-locus interactions among the DOCK7 (Montrer DOCK7 Anticorps), PCSK9 and GALNT2 (Montrer GALNT2 Anticorps) SNPs were also noted.
In this study, variants in PCSK9 had approximately the same effect as variants in HMGCR (Montrer HMGCR Anticorps) on the risk of cardiovascular events and diabetes per unit decrease in the LDL cholesterol level. The effects of these variants were independent and additive.
During sepsis, PCSK9 levels are highly correlated with the development of subsequent multiple organ failure. Inhibition of PCSK9 activity is an attractive target for treating the spectrum of sepsis and septic shock.
Report increased intestinal cholesterol absorption and elevated serum cholesterol in families with primary hypercholesterolemia without mutations in PCSK9.
Serum PCSK9 level is significantly elevated in coronary heart disease patients.
These data suggest that serum levels of PCSK9 may contribute to increased risk of subclinical carotid atherosclerosis independent of conventional risk factors.
Podocyte damage triggers marked inductions in plasma PCSK9, and knockout of Pcsk9 ameliorates dyslipidemia in a mouse model of nephrotic syndrome.
polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating PCSK9.
binding of PCSK9 to GRP94 (Montrer HSP90B1 Anticorps) protects LDLR (Montrer LDLR Anticorps) from degradation likely by preventing early binding of PCSK9 to LDLR (Montrer LDLR Anticorps)
The absence of PCSK9 results in a sex- and tissue-specific subcellular distribution of the LDLR (Montrer LDLR Anticorps) and VLDLR (Montrer VLDLR Anticorps), which is determined by estradiol levels.
that ox-LDL receptor-1 (Montrer OLR1 Anticorps) and PCSK9 positively influence each other's expression, especially during an inflammatory reaction
Data show that leptin (Montrer LEP Anticorps) treatment suppresses proprotein convertase subtilisin/kexin type 9 (PCSK9) in male, but fails to suppress PCSK9 in female.
The Liver Clock Controls Cholesterol Homeostasis through Trib1 (Montrer TRIB1 Anticorps) Protein-mediated Regulation of PCSK9/Low Density Lipoprotein Receptor (LDLR (Montrer LDLR Anticorps)) Axis.
Hepatic LDLR (Montrer LDLR Anticorps) levels are up-regulated in SEC24A (Montrer SEC24A Anticorps)-deficient cells as a consequence of specific dependence of PCSK9, a negative regulator of LDLR (Montrer LDLR Anticorps), on SEC24A (Montrer SEC24A Anticorps) for efficient exit from the ensoplasmic reticulum.
PCSK9(-/-) mice display normal sodium balance and blood pressure regulation despite an increase of cleaved alphaENaC (Montrer SCNN1A Anticorps) under basal condition
This gene encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. The encoded protein is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the endoplasmic reticulum. The protein may function as a proprotein convertase. This protein plays a role in cholesterol homeostasis and may have a role in the differentiation of cortical neurons. Mutations in this gene have been associated with a third form of autosomal dominant familial hypercholesterolemia (HCHOLA3).
proprotein convertase subtilisin/kexin type 9
, convertase subtilisin/kexin type 9 preproprotein
, neural apoptosis regulated convertase 1
, subtilisin/kexin-like protease PC9
, convertase subtilisin
, neural apoptosis-regulated convertase 1
, proprotein convertase 9
, proprotein convertase PC9
, proprotein convertase subtilisin/kexin type 9 preproprotein
, Proprotein convertase 9
, Subtilisin/kexin-like protease PC9